GAITHERSBURG, Md., June 4, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that it intends to offer to sell, subject to market and other conditions, $100 million of its common stock in an underwritten public offering. As part of this offering Novavax, Inc. intends to grant the underwriters a 30-day option to purchase up to an additional $15 million of its common stock. The success, the size and the terms of this offering cannot be guaranteed.
Help employers find you! Check out all the jobs and post your resume.
